Differential chemosensitivity of breast cancer cells to ganciclovir treatment following adenovirus-mediated herpes simplex virus thymidine kinase gene transfer

Cancer Gene Therapy

Volumn 6, Issue 2, 1999, Pages 179-190

  Li, Pei Xiang ^b   Ngo, Duc ^b   Brade, Anthony M ^b   Klamut, Henry J ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b NONE

Author keywords

Apoptosis; Breast cancer; Bystander effect; Ganciclovir treatment; Gene therapy; Herpes simplex virus thymidine kinase; p53 tumor suppressor gene

Indexed keywords

ACRIDINE ORANGE; DNA FRAGMENT; ETHIDIUM; FLUORESCENT DYE; GANCICLOVIR; PROTEIN BCL 2; PROTEIN P53; THYMIDINE KINASE;

ADENOVIRUS; APOPTOSIS; ARTICLE; BREAST TUMOR; CELL CULTURE; CELL SURVIVAL; DRUG EFFECT; GENE THERAPY; GENETIC TRANSDUCTION; GENETICS; HERPES SIMPLEX VIRUS; HUMAN; METABOLISM; NORTHERN BLOTTING; SENSITIVITY AND SPECIFICITY; TIME; WESTERN BLOTTING;

ACRIDINE ORANGE; ADENOVIRIDAE; APOPTOSIS; BLOTTING, NORTHERN; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL SURVIVAL; DNA FRAGMENTATION; ETHIDIUM; FLUORESCENT DYES; GANCICLOVIR; GENE THERAPY; HUMANS; PROTO-ONCOGENE PROTEINS C-BCL-2; SENSITIVITY AND SPECIFICITY; SIMPLEXVIRUS; THYMIDINE KINASE; TIME FACTORS; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033093015     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700005     Document Type: Article

References (98)

1. Moolten FL. Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther. 1994;1:279-287.
2. Freeman SM, Whartenby KA, Freeman JL, Abboud CN, Marrogi AJ. In situ use of suicide genes for cancer therapy. Semin Oncol. 1996;23:31-45.
3. Culver KW, Van Gilder J, Link CJ, et al. Gene therapy for the treatment of malignant brain tumors with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system. Hum Gene Ther. 1994;5:343-379.
4. O'Malley BW, Jr, Chen SH, Schwartz MR, Woo SL. Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. Cancer Res. 1995;55:1080-1085.
5. Bonnekoh B, Greenhalgh DA, Bundman DS, et al. Adenoviral-mediated herpes simplex virus-thymidine kinase gene transfer in vivo for treatment of experimental human melanoma. J Invest Dermatol. 1996;106:1163-1168.
6. Osaki T, Tanio Y, Tachibana I, et al. Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res. 1994;54:5258-5261.
7. Wills KN, Huang WM, Harris MP, Machemer T, Maneval DC, Gregory RJ. Gene therapy for hepatocellular carcinoma: chemosensitivity conferred by adenovirus-mediated transfer of the HSV-1 thymidine kinase gene. Cancer Gene Ther. 1995;2:191-197.
8. Aoki K, Yoshida T, Matsumoto N, et al. Gene therapy for peritoneal dissemination of pancreatic cancer by liposomemediated transfer of herpes simplex virus thymidine kinase gene. Hum Gene Ther. 1997;8:1105-1113.
9. Coll JL, Mesnil M, Lefebvre MF, Lancon A, Favrot MC. Long-term survival of immunocompetent rats with intraperitoneal colon carcinoma tumors using herpes simplex thymidine kinase/ganciclovir and IL-2 treatments. Gene Ther. 1997;4:1160-1166.
10. Eastham JA, Chen SH, Sehgal I, et al. Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum Gene Ther. 1996;7:515-523.
11. Link CJ, Jr, Moorman D, Seregina T, Levy JP, Schabold KJ. A phase I trial of in vivo gene therapy with the herpes simplex thymidine kinase/ganciclovir system for the treatment of refractory or recurrent ovarian cancer. Hum Gene Ther. 1996;7:1161-1179.
12. Manome Y, Abe M, Hagen MF, Fine HA, Kufe DW. Enhancer sequences of the DF3 gene regulate expression of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer cells to ganciclovir. Cancer Res. 1994;54:5408-5413.
13. Colak A, Goodman JC, Chen SH, Woo SL, Grossman RG, Shine HD. Adenovirus-mediated gene therapy in an experimental model of breast cancer metastatic to the brain. Hum Gene Ther. 1995;6:1317-1322.
14. Moolten FL, Vonderhaar BK, Mroz PJ. Transduction of the herpes thymidine kinase gene into premalignant murine mammary epithelial cells renders subsequent breast cancers responsive to ganciclovir therapy. Hum Gene Ther. 1996;7:1197-1204.
15. Yee D, McGuire SE, Brunner N, et al. Adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase in an ascites model of human breast cancer. Hum Gene Ther. 1996;7:1251-1257.
16. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science. 1992;256:1550-1552.
17. Freeman SM, Abboud CN, Whartenby KA, et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993;53: 5274-5283.
18. Bi WL, Parysek LM, Warnick R, Stambrook PJ. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum Gene Ther. 1993;4:725-731.
19. Fick J, Barker FG, Dazin P, Westphale EM, Beyer EC, Israel MA. The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc Natl Acad Sci USA. 1995;92: 11071-11075.
20. Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA. 1996;93:1831-1835.
21. Ishii-Morita H, Agbaria R, Mullen CA, et al. Mechanism of "bystander effect" killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Ther. 1997;4:244-251.
22. Samejima Y, Meruelo D. "Bystander killing" induces apoptosis and is inhibited by forskolin. Gene Ther. 1995;2: 50-58.
23. Wallace H, Clarke AR, Harrison DJ, Hooper ML, Bishop JO. Ganciclovir-induced ablation non-proliferating thyrocytes expressing herpesvirus thymidine kinase occurs by p53-independent apoptosis. Oncogene. 1996;13:55-61.
24. Hamel W, Magnelli L, Chiarugi VP, Israel MA. Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells. Cancer Res. 1996;56:2697-2702.
25. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26:239-257.
26. White E. Life, death, and the pursuit of apoptosis. Genes Dev. 1996;10:1-15.
27. Wyllie AH. The genetic regulation of apoptosis. Curr Opin Genet Dev. 1995;5:97-104.
28. Lund LR, Romer J, Thomasset N, et al. Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and -dependent pathways. Development. 1996;122:181-193.
29. Clarke AR, Purdie CA, Harrison DJ, et al. Thymocyte apoptosis induced by p53-dependent and -independent pathways. Nature. 1993;362:849-852.
30. Symonds H, Krall L, Remington L, et al. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell. 1994;78:703-711.
31. Liebermann DA, Hoffman B, Steinman RA. Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways. Oncogene. 1995;11:199-210.
32. Vaux DL, Strasser A. The molecular biology of apoptosis. Proc Natl Acad Sci USA. 1996;93:2239-2244.
33. Nagata S. Apoptosis by death factor. Cell. 1997;88:355-365.
34. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature. 1997;389: 300-305.
35. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993;74:957-967.
36. Lowe SW, Jacks T, Housman DE, Ruley HE. Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proc Natl Acad Sci USA. 1994;91:2026-2030.
37. Smith ML, Fornace AJ, Jr. Genomic instability and the role of p53 mutations in cancer cells. Curr Opin Oncol. 1995;7:69-75.
38. Anthoney DA, McIlwrath AJ, Gallagher WM, Edlin AR, Brown R. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer Res. 1996;56:1374-1381.
39. St Clair MH, Lambe CU, Furman PA. Inhibition by ganciclovir of cell growth and DNA synthesis of cells biochemically transformed with herpesvirus genetic information. Antimicrob Agents Chemother. 1987;31:844-849.
40. Foti M, Marshalko S, Schurter E, Kumar S, Beardsley GP, Schweitzer BI. Solution structure of a DNA decamer containing the antiviral drug ganciclovir: combined use of NMR, restrained molecular dynamics, and full relaxation matrix refinement. Biochemistry. 1997;36:5336-5345.
41. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science. 1994;266:1821-1828.
42. Murray AW. Creative blocks: cell-cycle checkpoints and feedback controls. Nature. 1992;359:599-604.
43. O'Connor PM, Kohn KW. A fundamental role for cell cycle regulation in the chemosensitivity of cancer cells? Semin Cancer Biol. 1992;3:409-416.
44. Hickman JA. Apoptosis and chemotherapy resistance. Eur J Cancer. 1996;32A:921-926.
45. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature. 1991;351:453-456.
46. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wildtype p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA. 1992;89:7491-7495.
47. 1 arrest in human cancer cells. Cancer Res. 1995;55:5187-5190.
48. Bellamy CO. p53 and apoptosis. Br Med Bull. 1997;53: 522-538.
49. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253:49-53.
50. Levine AJ, Wu MC, Chang A, et al. The spectrum of mutations at the p53 locus: evidence for tissue-specific mutagenesis, selection of mutant alleles, and a "gain of function" phenotype. Ann NY Acad Sci. 1995;768:111-128.
51. Lee JM, Bernstein A. p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA. 1993;90:5742-5746.
52. Riou G, Le MG, Travagli JP, Levine AJ, Moll UM. Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma. J Natl Cancer Inst. 1993;85:1765-1767.
53. Lowe SW, Bodis S, McClatchey A, et al. p53 status and the efficacy of cancer therapy in vivo. Science. 1994;266: 807-810.
54. Fan S, Smith ML, Rivet DJ, et al. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res. 1995;55:1649-1654.
55. Mcllwrath AJ, Vasey PA, Ross GM, Brown R. Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res. 1994;54:3718-3722.
56. O'Connor PM, Jackman J, Bae I, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 1997;57:4285-4300.
57. Beck C, Cayeux S, Lupton SD, Dorken B, Blankenstein T. The thymidine kinase/ganciclovir-mediated "suicide" effect is variable in different tumor cells. Hum Gene Ther. 1995;6:1525-1530.
58. Sturtz FG, Waddell K, Shulok J, et al. Variable efficiency of the thymidine kinase/ganciclovir system in human glioblastoma cell lines: implications for gene therapy. Hum Gene Ther. 1997;8:1945-1953.
59. Denning C, Pitts JD. Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes. Hum Gene Ther. 1997;8:1825-1835.
60. Wosikowski K, Regis JT, Robey RW, et al. Normal p53 status and function despite the development of drug resistance in human breast cancer cells. Cell Growth Differ. 1995;6:1395-1403.
61. Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature. 1989;342:705-708.
62. Celis A, Celis JE. General procedures for tissue culture. In: JE Celis, ed. Cell Biology: A Laboratory Handbook San Diego: Academic Press; 1994.
63. Zhang WW, Alemany R, Wang J, Koch PE, Ordonez NG, Roth JA. Safety evaluation of Ad5CM V-p53 in vitro and in vivo. Hum Gene Ther. 1995;6:155-164.
64. Li P, Bui T, Gray D, Klamut HJ. Therapeutic potential of recombinant p53 overexpression in breast cancer cells expressing endogenous wild-type p53. Breast Cancer Res Treat. 1998;48:273-286.
65. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. New York: Cold Spring Harbor Laboratory Press; 1989.
66. Feinberg AP, Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem. 1983;132:6-13.
67. Brezden CB, Rauth AM. Differential cell death in immortalized and non-immortalized cells at confluency. Oncogene. 1996;12:201-206.
68. Harlow E, Lane D. Antibodies: A Laboratory Manual. New York: Cold Spring Harbor Laboratory Press; 1988.
69. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991;51:6304-6311.
70. Lane DP. Cancer: p53, guardian of the genome. Nature. 1992;358:15-16.
71. Ogretmen B, Safa AR. Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug-resistant MCF-7/Adr human breast cancer cells. Oncogene. 1997;14:499-506.
72. Wosikowski K, Regis JT, Robey RW, et al. Normal p53 status and function despite the development of drug resistance in human breast cancer cells. Cell Growth Differ. 1995;6:1395-1403.
73. Elstner E, Linker-Israeli M, Said J, et al. 20-epi-vitamin D3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res. 1995;55:2822-2830.
74. Zapata JM, Krajewska M, Krajewski S, et al. Expression of multiple apoptosis-regulatory genes in human breast cancer cell lines and primary tumors. Breast Cancer Res Treat. 1998;47:129-140.
75. O'Connor PM, Jackman J, Jondle D, Bhatia K, Magrath I, Kohn KW. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res. 1993;53:4776-4780.
76. Zhan Q, Fan S, Bae I, et al. Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis [published erratum appears in Oncogene. 1995; 10:1259]. Oncogene 1994;9:3743-3751.
77. Fairchild CR, Ivy SP, Kao-Shan CS, et al. Isolation of amplified and overexpressed DNA sequences from adriamycin-resistant human breast cancer cells. Cancer Res. 1987;47:5141-5148.
78. Sinha BK, Haim N, Dusre L, Kerrigan D, Pommier Y. DNA strand breaks produced by etoposide (VP-16,213) in sensitive and resistant human breast tumor cells: implications for the mechanism of action. Cancer Res. 1988;48: 5096-5100.
79. Alaoui-Jamali MA, Batist G, Lehnert S. Radiation-induced damage to DNA in drug- and radiation-resistant sublines of a human breast cancer cell line. Radiat Res. 1992;129:37-42.
80. Takenaga K, Tagawa M, Sakiyama S. Therapeutic potency of transduction with herpes simplex virus thymidine kinase gene against multidrug-resistant mouse leukemia cells. Anticancer Res. 1996;16:681-685.
81. Smythe WR, Hwang HC, Elshami AA, Amin KM, Albelda SM, Kaiser LR. Differential sensitivity of thoracic malignant tumors to adenovirus-mediated drug sensitization gene therapy. J Thorac Cardiovasc Surg. 1995;109:626-630.
82. Fang X, Parkinson FE, Mowles DA, Young JD, Cass CE. Functional characterization of a recombinant sodium-dependent nucleoside transporter with selectivity for pyrimidine nucleosides (cNT1rat) by transient expression in cultured mammalian cells. Biochem J. 1996;317:457-465.
83. Belt JA, Marina NM, Phelps DA, Crawford CR. Nucleoside transport in normal and neoplastic cells. Adv Enzyme Regul. 1993;33:235-252.
84. Hooper ML, Subak-Sharpe JH. Metabolic cooperation between cells. Int Rev Cytol. 1981;69:45-104.
85. Patterson AV, Zhang H, Moghaddam A, et al. Increased sensitivity to the prodrug 5′-deoxy-5-fluorouridine and modulation of 5-fluoro-2′-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Br J Cancer. 1995;72:669-675.
86. Chen L, Waxman DJ, Chen D, Kufe DW. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. Cancer Res. 1996;56:1331-1340.
87. Reed JC, Miyashita T, Takayama S, et al. BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem. 1996;60:23-32.
88. Silvestrini R, Benini E, Veneroni S, et al. p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol. 1996; 14:1604-1610.
89. Chiou SK, Rao L, White E. Bcl-2 blocks p53-dependent apoptosis [published erratum appears in Mol Cell Biol. 1994;14:4333]. Mol Cell Biol. 1994;14:2556-2563.
90. Strasser A, Harris AW, Jacks T, Cory S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell. 1994; 79:329-339.
91. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993;74:609-619.
92. L. Nature. 1996;379:554-556.
93. Takayama S, Sato T, Krajewski S, et al. Cloning and functional analysis of BAG-1: a novel Bcl-2-binding protein with anti-cell death activity. Cell. 1995;80:279-284.
94. L and Bcl-2, displaces Bax and promotes cell death. Cell. 1995; 80:285-291.
95. L. J Biol Chem. 1996;271:6306-6312.
96. Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci USA. 1993;90:3516-3520.
97. Zhan Q, Bieszczad CK, Bae I, Fornace AJ, Jr, Craig RW. Induction of BCL2 family member MCL1 as an early response to DNA damage. Oncogene. 1997;14:1031-1039.
98. L or bax proteins in multidrug-resistant MCF-7/Adr human breast cancer cells. Int J Cancer. 1996;67:608-614.